Moleculin Biotech, Inc. — Q2 2021 Form 10-Q
Reporting period: Three and six months ended June 30, 2021. Unaudited figures below are in millions of dollars unless otherwise stated. Moleculin is a clinical-stage pharmaceutical company developing treatments for resistant cancers and viruses; it has not generated revenue.
Financial results and liquidity
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $3.039 | $3.329 | $7.145 | $6.535 |
| General and administrative expense | $2.434 | $1.653 | $4.373 | $3.463 |
| Total operating expenses | $5.517 | $5.034 | $11.606 | $10.096 |
| Net loss | $4.244 | $10.112 | $8.689 | $11.321 |
| Basic and diluted loss per share | $0.15 | $1.02 | $0.35 | $1.24 |
- Operating margin is not meaningful because the company had no revenue and incurred operating losses.
- Cash and cash equivalents were $79.506 million at June 30, 2021, versus $15.173 million at December 31, 2020. Current assets were $81.836 million and current liabilities $3.350 million.
- Six-month operating cash use was $10.405 million, compared with $9.275 million in the prior-year period. Investing cash use was zero; financing provided $74.748 million, principally from equity sales.
- Total liabilities were $8.834 million, including a $5.390 million warrant liability and lease liabilities. The filing reports no conventional borrowings or debt balance.
Changes versus the prior comparable period
- Q2 net loss narrowed from $10.112 million to $4.244 million, substantially reflecting a swing in warrant revaluation: a $1.173 million gain in Q2 2021 versus a $5.099 million loss in Q2 2020. For the six-month periods, the warrant revaluation was a $2.750 million gain in 2021 versus a $1.254 million loss in 2020.
- Six-month operating expenses rose $1.510 million. R&D increased $0.610 million, primarily with greater clinical activity and drug-product manufacturing; G&A increased $0.910 million, mainly due to consulting and advisory fees and corporate insurance.
- Operating cash use increased by $1.130 million year over year. Financing cash inflows were much higher following 2021 equity offerings.
- Shares outstanding increased from 11,536,720 at year-end 2020 to 28,552,213 at June 30, 2021, reflecting substantial equity issuance. The company completed a 1-for-6 reverse split in January 2021; per-share data was adjusted retroactively.
Business developments, outlook, and risks
- The pipeline includes Annamycin, the WP1066 portfolio and the WP1122 portfolio. The company reported six candidates, three of which had shown human activity in clinical trials.
- Annamycin trials included an ongoing Phase 1/2 AML study in Poland and a U.S. Phase 1b/2 study for soft-tissue sarcoma lung metastases, for which the first subject was dosed in June. In the Polish AML study, preliminary results in three patients receiving a full 240 mg/m² course indicated clinical benefit; the company also disclosed transient elevated liver enzymes in two patients and a protocol amendment to continue dose escalation. These are preliminary, small-cohort observations, not established efficacy.
- The company planned further Annamycin trials, including combination treatment with Ara-C, and described grants expected to support certain Poland-based studies. Timing and commencement remain uncertain.
- The MD Anderson-sponsored WP1066 adult brain-tumor trial was expected to close after the sponsoring physician’s departure; the company was seeking to continue similar research elsewhere. The Emory pediatric brain-tumor study continued dose escalation.
- In August 2021, the company submitted a U.K. clinical trial application for a Phase 1 WP1122 study in healthy volunteers and intended to pursue a U.S. cancer-related IND. Regulatory approval and subsequent development are not assured.
- Management said June 30 cash was expected to fund projected operating requirements into 2024, including forecast increased R&D spending. It expects operating losses for several years and no positive operating cash flow in the near future; projections depend on planned activities and may change. Additional financing may be needed, with no assurance it will be available on acceptable terms.
- The February public offering generated approximately $78.0 million gross proceeds. A $50 million ATM facility and a Lincoln Park agreement for up to $20 million of stock purchases were also established; the filing said there had been no sales under the new ATM as of the report date. Further equity funding could dilute shareholders.
- COVID-19 had slowed recruitment and constrained monitoring at some Polish trial sites, although the company reported some improvement. Drug supply had experienced limited interruption; further operational effects remain uncertain. The company relies on third parties for manufacturing and has no sales organization.
- Other unusual items include a $2.750 million six-month noncash warrant-liability revaluation gain, which affects reported losses but not operating cash flow. The warrant liability is measured using Level 3 inputs. No material changes to previously disclosed risk factors and no legal proceedings were reported.
Important facts for investors to verify
- Whether cash burn and clinical spending remain consistent with management’s forecast that available cash would fund operations into 2024.
- Updated enrollment, safety, dose-escalation and efficacy data for Annamycin and WP1066 trials, including the context and follow-up for the preliminary AML observations.
- Regulatory progress and trial timing for WP1122, Annamycin combination studies, and planned or grant-funded studies.
- Actual use of the ATM and Lincoln Park facilities, resulting proceeds, and dilution from future share issuance and outstanding warrants.
- Whether COVID-19, third-party manufacturing, licensing arrangements, or reliance on external collaborators materially affect trial timelines, supply or funding.